Brezivaptan

Brezivaptan
Clinical data
Other namesTS-121; TS121; TS-1211; TS1211; THY1773; THY-1773; ANC-501; ANC501
Routes of
administration		By mouth
Identifiers
  • 2-[3-(3-chlorophenyl)-1-[4-(2-morpholin-4-ylethyl)phenyl]-5-oxo-1,2,4-triazol-4-yl]-N-propan-2-ylacetamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC25H30ClN5O3
Molar mass484.00 g·mol−1
3D model (JSmol)
  • CC(C)NC(=O)CN1C(=NN(C1=O)C2=CC=C(C=C2)CCN3CCOCC3)C4=CC(=CC=C4)Cl
  • InChI=1S/C25H30ClN5O3/c1-18(2)27-23(32)17-30-24(20-4-3-5-21(26)16-20)28-31(25(30)33)22-8-6-19(7-9-22)10-11-29-12-14-34-15-13-29/h3-9,16,18H,10-15,17H2,1-2H3,(H,27,32)
  • Key:YCLGGNJZGIFVKX-UHFFFAOYSA-N

Brezivaptan (developmental code names ANC-501, THY-1773, TS-121) is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder. As of November 2022, it is in phase II clinical trials for this indication.

See also

References

  1. ↑ PubChem. "Brezivaptan". pubchem.ncbi.nlm.nih.gov. Retrieved 2024-08-15.
  2. 1 2 "TS 121 -". AdisInsight. Springer Nature Switzerland AG.
  3. 1 2 "New Drug Pipeline - Taisho Pharmaceutical Holdings".
  4. ↑ Kamiya M, Sabia HD, Marella J, Fava M, Nemeroff CB, Umeuchi H, Iijima M, Chaki S, Nishino I (September 2020). "Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study". Journal of Psychiatric Research. 128: 43–51. doi:10.1016/j.jpsychires.2020.05.017. PMID 32521250. S2CID 219587135.
  5. ↑ Inatani S, Mizuno-Yasuhira A, Kamiya M, Nishino I, Sabia HD, Endo H (May 2021). "Prediction of a clinically effective dose of THY1773, a novel V1B receptor antagonist, based on preclinical data". Biopharmaceutics & Drug Disposition. 42 (5): 204–217. doi:10.1002/bdd.2273. PMC 8252455. PMID 33734452.